表纸
市场调查报告书

未分化淋巴瘤激酶(ALK)抑制剂的全球市场:2020年-2024年

Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品编码 943477
出版日期 内容资讯 英文 120 Pages
订单完成后即时交付
价格
未分化淋巴瘤激酶(ALK)抑制剂的全球市场:2020年-2024年 Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2020-2024
出版日期: 2020年06月09日内容资讯: 英文 120 Pages
简介

未分化淋巴瘤激酶(ALK)抑制剂市场在2020年~2024年间,预测将以20%的年复合成长率推移,并成长到29亿6000万美元的规模。

本报告提供未分化淋巴瘤激酶(ALK)抑制剂市场调查,提供市场概要,市场成长要素及阻碍因素分析,各类型·各地区的市场规模的变化与预测,供应商分析,市场机会等全面性资讯。

目录

摘要整理

市场形势

市场规模

  • 市场定义
  • 市场区隔分析
  • 2019年的市场规模
  • 市场预测:从2019年~2024年的预测

波特的五力分析

各类型市场区隔

  • 市场·市场区隔
  • 各类型比较
  • 第2代ALK抑制剂-市场规模与预测(2019年-2024年)
  • 第1代ALK抑制剂-市场规模与预测(2019年-2024年)
  • 第3代ALK抑制剂-市场规模与预测(2019年-2024年)
  • 各类型的市场机会

客户形势

各地区形势

  • 各地区市场区隔
  • 各地区比较
  • 北美 -市场规模与预测(2019年-2024年)
  • 欧洲-市场规模与预测(2019年-2024年)
  • 亚洲-市场规模与预测(2019年-2024年)
  • 其他地区-市场规模与预测(2019年-2024年)
  • 主要国家
  • 地区的市场机会
  • 成长要素-需求
  • 成长要素-外部要素
  • 市场课题
  • 市场趋势

业者情势

  • 概况
  • 业者情势
  • 创造性破坏状况

供应商分析

  • 交易厂商
  • 供应商的市场定位
  • AstraZeneca Plc
  • Betta Pharmaceuticals Co. Ltd.
  • Bio-Techne Corp.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Turning Point Therapeutics Inc.

附录

目录
Product Code: IRTNTR43929

Technavio has been monitoring the anaplastic lymphoma kinase (ALK) inhibitors market and it is poised to grow by $ 2.96 bn during 2020-2024 progressing at a CAGR of 20% during the forecast period. Our reports on anaplastic lymphoma kinase (ALK) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high target affinity and specificity of ALK inhibitors and high prevalence of lung cancer. In addition, high target affinity and specificity of ALK inhibitors is anticipated to boost the growth of the market as well.

The anaplastic lymphoma kinase (ALK) inhibitors market analysis includes type segment and geographical landscapes

Technavio's ‘ anaplastic lymphoma kinase (ALK) inhibitors market ’ is segmented as below:

By Type:

  • Second-generation ALK inhibitors
  • First-generation ALK inhibitors
  • Third-generation ALK inhibitors

By Geography: landscapes

  • North America
  • Europe
  • Asia
  • ROW

This study identifies by the presence of patient assistance programs as one of the prime reasons driving the anaplastic lymphoma kinase (ALK) inhibitors market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our anaplastic lymphoma kinase (ALK) inhibitors market covers the following areas:

  • Anaplastic lymphoma kinase (ALK) inhibitors market sizing
  • Anaplastic lymphoma kinase (ALK) inhibitors market forecast
  • Anaplastic lymphoma kinase (ALK) inhibitors market industry analysis"

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anaplastic lymphoma kinase (ALK) inhibitors market vendors that include AstraZeneca Plc, Betta Pharmaceuticals Co. Ltd., Bio-Techne Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck KGaA, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Turning Point Therapeutics Inc.. Also, the anaplastic lymphoma kinase (ALK) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type

  • Market segments
  • Comparison by Type
  • Second-generation ALK inhibitors - Market size and forecast 2019-2024
  • First-generation ALK inhibitors - Market size and forecast 2019-2024
  • Third-generation ALK inhibitors - Market size and forecast 2019-2024
  • Market opportunity by Type

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Volume drivers - Demand led growth
  • Volume drivers - External factors
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AstraZeneca Plc
  • Betta Pharmaceuticals Co. Ltd.
  • Bio-Techne Corp.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Turning Point Therapeutics Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Type - Market share 2019-2024 (%)
  • 22: Comparison by Type
  • 23: Second-generation ALK inhibitors - Market size and forecast 2019-2024 ($ million)
  • 24: Second-generation ALK inhibitors - Year-over-year growth 2019-2024 (%)
  • 25: First-generation ALK inhibitors - Market size and forecast 2019-2024 ($ million)
  • 26: First-generation ALK inhibitors - Year-over-year growth 2019-2024 (%)
  • 27: Third-generation ALK inhibitors - Market size and forecast 2019-2024 ($ million)
  • 28: Third-generation ALK inhibitors - Year-over-year growth 2019-2024 (%)
  • 29: Market opportunity by Type
  • 30: Customer landscape
  • 31: Market share by geography 2019-2024 (%)
  • 32: Geographic comparison
  • 33: North America - Market size and forecast 2019-2024 ($ million)
  • 34: North America - Year-over-year growth 2019-2024 (%)
  • 35: Europe - Market size and forecast 2019-2024 ($ million)
  • 36: Europe - Year-over-year growth 2019-2024 (%)
  • 37: Asia - Market size and forecast 2019-2024 ($ million)
  • 38: Asia - Year-over-year growth 2019-2024 (%)
  • 39: ROW - Market size and forecast 2019-2024 ($ million)
  • 40: ROW - Year-over-year growth 2019-2024 (%)
  • 41: Key leading countries
  • 42: Market opportunity by geography ($ million)
  • 43: Impact of drivers and challenges
  • 44: Vendor landscape
  • 45: Landscape disruption
  • 46: Industry risks
  • 47: Vendors covered
  • 48: Market positioning of vendors
  • 49: AstraZeneca Plc - Overview
  • 50: AstraZeneca Plc - Product and service
  • 51: AstraZeneca Plc - Key offerings
  • 52: AstraZeneca Plc - Key customers
  • 53: AstraZeneca Plc - Segment focus
  • 54: Betta Pharmaceuticals Co. Ltd. - Overview
  • 55: Betta Pharmaceuticals Co. Ltd. - Product and service
  • 56: Betta Pharmaceuticals Co. Ltd. - Key offerings
  • 57: Betta Pharmaceuticals Co. Ltd. - Key customers
  • 58: Betta Pharmaceuticals Co. Ltd. - Segment focus
  • 59: Bio-Techne Corp. - Overview
  • 60: Bio-Techne Corp. - Business segments
  • 61: Bio-Techne Corp. - Key offerings
  • 62: Bio-Techne Corp. - Key customers
  • 63: Bio-Techne Corp. - Segment focus
  • 64: F. Hoffmann-La Roche Ltd. - Overview
  • 65: F. Hoffmann-La Roche Ltd. - Business segments
  • 66: F. Hoffmann-La Roche Ltd. - Key offerings
  • 67: F. Hoffmann-La Roche Ltd. - Key customers
  • 68: F. Hoffmann-La Roche Ltd. - Segment focus
  • 69: GlaxoSmithKline Plc - Overview
  • 70: GlaxoSmithKline Plc - Business segments
  • 71: GlaxoSmithKline Plc - Key offerings
  • 72: GlaxoSmithKline Plc - Key customers
  • 73: GlaxoSmithKline Plc - Segment focus
  • 74: Merck KGaA - Overview
  • 75: Merck KGaA - Business segments
  • 76: Merck KGaA - Key offerings
  • 77: Merck KGaA - Key customers
  • 78: Merck KGaA - Segment focus
  • 79: Novartis AG - Overview
  • 80: Novartis AG - Business segments
  • 81: Novartis AG - Key offerings
  • 82: Novartis AG - Key customers
  • 83: Novartis AG - Segment focus
  • 84: Pfizer Inc. - Overview
  • 85: Pfizer Inc. - Business segments
  • 86: Pfizer Inc. - Key offerings
  • 87: Pfizer Inc. - Key customers
  • 88: Pfizer Inc. - Segment focus
  • 89: Takeda Pharmaceutical Co. Ltd. - Overview
  • 90: Takeda Pharmaceutical Co. Ltd. - Product and service
  • 91: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 92: Takeda Pharmaceutical Co. Ltd. - Key customers
  • 93: Takeda Pharmaceutical Co. Ltd. - Segment focus
  • 94: Turning Point Therapeutics Inc. - Overview
  • 95: Turning Point Therapeutics Inc. - Product and service
  • 96: Turning Point Therapeutics Inc. - Key offerings
  • 97: Turning Point Therapeutics Inc. - Key customers
  • 98: Turning Point Therapeutics Inc. - Segment focus
  • 99: Currency conversion rates for US$
  • 100: Research Methodology
  • 101: Validation techniques employed for market sizing
  • 102: Information sources
  • 103: List of abbreviations